{"code":"Q2055","short_description":"Idecabtagene vicleucel car","long_description":"Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose","status":"active","section":"Q-codes: Temporary Codes","category":"Temporary","effective_date":"2024-04-04","termination_date":null,"replacement_code":"","opps_status_indicator":"K","opps_status_label":"Non-pass-through drugs and biologicals","opps_apc":"9422","fee_schedules":[],"mue":[],"drug_classes":[],"ndc_crosswalk":[{"ndc":"59572-0515-01","drug_name":"Abecma","dosage":"UP TO 510 million autologous anti-BCMA CAR-positive viable T cells","unit":"1","labeler_name":"Celgene Corporation"},{"ndc":"59572-0515-02","drug_name":"Abecma","dosage":"UP TO 460 million autologous anti-BCMA CAR-positive viable T cells","unit":"1","labeler_name":"Celgene Corporation"},{"ndc":"59572-0515-03","drug_name":"Abecma","dosage":"UP TO 460 million autologous anti-BCMA CAR-positive viable T cells","unit":"1","labeler_name":"Celgene Corporation"}],"utilization":[],"urls":{"self_html":"https:\/\/hcpcslookup.com\/codes\/q2055","self_json":"https:\/\/hcpcslookup.com\/api\/codes\/Q2055.json"}}